AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8921786 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI grade 2 flow at 90 minutes improving to TIMI grade 3 flow at follow-up (5-7 days)
Number of subjects: 914
Study 8921786 — intervention group
Group type: COMPARATOR
Intervention: TIMI grade 2 flow at 90 minutes
Number of subjects: 914
Study 8921786 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement from TIMI grade 2 to TIMI grade 3 flow
Number of subjects: 914
Study 8921786 — intervention group
Group type: COMPARATOR
Intervention: Persistent TIMI grade 2 flow
Number of subjects: 914
Study 2155958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg, two puffs, four times per day for 12 weeks)
Number of subjects: 188
Study 2155958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two puffs, four times per day for 12 weeks)
Number of subjects: 188
Study 7428402 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vincamine
Number of subjects: 8
Study 7428402 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 31862004 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg loading dose and 30 mg/kg/h continuous maintenance infusion for 1 h (group H)
Number of subjects: 69
Study 31862004 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg/kg loading dose and 15 mg/kg/h continuous maintenance infusion for 1 h (group L)
Number of subjects: 69
Study 31862004 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% saline infusion)
Number of subjects: 69
Study 27736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus feedback (MIF)
Number of subjects: 242
Study 27736113 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (control)
Number of subjects: 242
Study 27736113 — intervention group
Group type: COMPARATOR
Intervention: Both MIF and control
Number of subjects: 242
Study 26092195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant, natural sounds via headphones for 90 minutes
Number of subjects: 60
Study 25227540 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental muscle vibration (SMV) + exercise (120 Hz SMV over biceps brachii and flexor carpi ulnaris)
Number of subjects: 22
Study 25227540 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (Control Group)
Number of subjects: 22
Study 22170479 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod 100 mg/day for 4 weeks (stage 1)
Number of subjects: 29
Study 22170479 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod 100 mg/day for 8 weeks (stage 2)
Number of subjects: 29
Study 22170479 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod 100 mg twice a day for 8 weeks (stage 3)
Number of subjects: 29
Study 22170479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16824688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung age and respiratory symptoms feedback
Number of subjects: 124
Study 16824688 — intervention group
Group type: COMPARATOR
Intervention: Brochure containing facts about smoking
Number of subjects: 124
Study 15725132 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL of terminal warm blood cardioplegia (TWBC)
Number of subjects: 50
Study 15725132 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of terminal warm blood cardioplegia (TWBC)
Number of subjects: 50
Study 12034651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 40 mg/d
Number of subjects: 50
Study 12034651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 80 mg/d
Number of subjects: 50
Study 12034651 — intervention group
Group type: COMPARATOR
Intervention: Statin-80 (atorvastatin or simvastatin 80 mg/d)
Number of subjects: 50
Study 9224205 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate (n = 10)
Number of subjects: 30
Study 9224205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study 8017672 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (6-10 mg.kg-1.h-1)
Number of subjects: 50
Study 8017672 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-isoflurane (isoflurane continuously injected)
Number of subjects: 50
Study 8017672 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 50
Study 8017672 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-isoflurane (group I)
Number of subjects: 50
Study 8017672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 3305743 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning transcutaneous electrical nerve stimulator
Number of subjects: 26
Study 3305743 — intervention group
Group type: COMPARATOR
Intervention: Non-functioning transcutaneous electrical nerve stimulator
Number of subjects: 26
Study 29024230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mol/L GABA
Number of subjects: 30
Study 29024230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mol/L GABA
Number of subjects: 30
Study 29024230 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 30
Study 29024230 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study 27623538 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (lecture followed by group discussion and information booklet)
Number of subjects: 203
Study 27623538 — intervention group
Group type: COMPARATOR
Intervention: Information booklet
Number of subjects: 203
Study 27623538 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program
Number of subjects: 203
Study 24790012 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (ExBR) - rowing ergometry 6 days/week and supplemental strength training 2 days/week
Number of subjects: 27
Study 24790012 — intervention group
Group type: COMPARATOR
Intervention: Sedentary bed rest (BR)
Number of subjects: 27
Study 22564503 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of study event rates
Number of subjects: 116
Study 22564503 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute risk differences
Number of subjects: 116
Study 22564503 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information in table cells
Number of subjects: 116
Study 22564503 — intervention group
Group type: EXPERIMENTAL
Intervention: Time frame information in tables
Number of subjects: 116
Study 22564503 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk differences
Number of subjects: 116
Study 20608354 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 6
Study 20608354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study 18551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol at doses up to 300 mg/day
Number of subjects: 84
Study 18551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol at doses of 25, 50, or 100 mg three times daily
Number of subjects: 84
Study 18551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 84
Study 18551622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16075861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clindamycin (outpatient treatment)
Number of subjects: 58
Study 16075861 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ampicillin/sulbactam (inpatient treatment)
Number of subjects: 58
Study 11788637 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg T enanthate
Number of subjects: 61
Study 11788637 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg T enanthate
Number of subjects: 61
Study 11788637 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg T enanthate
Number of subjects: 61
Study 11788637 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg T enanthate
Number of subjects: 61
Study 11788637 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg T enanthate
Number of subjects: 61
Study 11788637 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (control)
Number of subjects: 61
Study 9872813 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microgram twice daily via Turbohaler)
Number of subjects: 14
Study 8750401 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 161
Study 8750401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 1812149 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch-based relaxation
Number of subjects: 34
Study 1812149 — intervention group
Group type: COMPARATOR
Intervention: Postural relaxation/rest
Number of subjects: 34
Study 6414252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (750 mg bolus injection followed by oral therapy)
Number of subjects: 40
Study 6414252 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (conventional therapy)
Number of subjects: 40
Study 6414252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 40
Study 6414252 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 40
Study 31712584 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg acute dose)
Number of subjects: 19
Study 31712584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30388067 — intervention group
Group type: EXPERIMENTAL
Intervention: Shows rated TV-14
Number of subjects: 1220
Study 30388067 — intervention group
Group type: EXPERIMENTAL
Intervention: Shows rated TV-MA
Number of subjects: 1220
Study 27591918 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Anxiety ABM
Number of subjects: 86
Study 27591918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ABM
Number of subjects: 86
Study 27591918 — intervention group
Group type: COMPARATOR
Intervention: Social Anxiety Control
Number of subjects: 86
Study 27591918 — intervention group
Group type: COMPARATOR
Intervention: Alcohol Control
Number of subjects: 86
Study 24569485 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (INS)
Number of subjects: 58
Study 24569485 — intervention group
Group type: COMPARATOR
Intervention: Triple oral therapy (TOT) with metformin, glyburide, and pioglitazone
Number of subjects: 58
Study 22150786 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 118
Study 22150786 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 118
Study 19013011 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (tamsulosin 0.4 mg and dutasteride 0.5 mg)
Number of subjects: 4844
Study 19013011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride monotherapy
Number of subjects: 4844
Study 19013011 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 4844
Study 18437789 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15894842 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestrained
Number of subjects: 12
Study 15894842 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist restraint in front
Number of subjects: 12
Study 15894842 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist restraint behind
Number of subjects: 12
Study 12188237 — intervention group
Group type: COMPARATOR
Intervention: Fiberglass (FG) short leg casts
Number of subjects: 156
Study 12188237 — intervention group
Group type: COMPARATOR
Intervention: Fiberglass (FG) short arm casts
Number of subjects: 156
Study 12188237 — intervention group
Group type: COMPARATOR
Intervention: Plaster of Paris (POP) short leg casts
Number of subjects: 156
Study 12188237 — intervention group
Group type: COMPARATOR
Intervention: Plaster of Paris (POP) short arm casts
Number of subjects: 156
Study 9437310 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE/PC‐IOL
Number of subjects: 3400
Study 9437310 — intervention group
Group type: COMPARATOR
Intervention: ICCE‐AG
Number of subjects: 3400
Study 7652119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranially recorded Mismatch Negativity (MMN) to tonal frequency changes
Number of subjects: 0
Study 7652119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranially recorded MMN
Number of subjects: 0
Study 7652119 — intervention group
Group type: COMPARATOR
Intervention: Attention-dependent N2 and P3 responses to frequency change
Number of subjects: 0
Study 2499481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous SMS 201‐995 (1.7, 0.8, 0.2, and 0.1 micrograms min‐1 for Groups A, B, C, and D respectively)
Number of subjects: 25
Study 2499481 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous SMS 201‐995 (25 micrograms for Group E)
Number of subjects: 25
Study 2499481 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 25
Study 370535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 0
Study 370535 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclophosphamide
Number of subjects: 0
Study 30291181 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual outpatient clinic (VOPC)
Number of subjects: 209
Study 30291181 — intervention group
Group type: COMPARATOR
Intervention: Actual outpatient clinic (OPC)
Number of subjects: 209
Study 27696012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent anticoagulation using NOACs for 48 hours to 1 week based on daily ECG monitoring; patients transmitted daily ECGs using an iPhone-based device.
Number of subjects: 58
Study 27696012 — intervention group
Group type: COMPARATOR
Intervention: Continuous anticoagulation using NOACs.
Number of subjects: 58
Study 26092816 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (OFS)
Number of subjects: 4717
Study 26092816 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian function suppression (OFS)
Number of subjects: 4717
Study 24245553 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational course in skin-protective behaviour and written information about skin care, with access to usual care and treatment.
Number of subjects: 742
Study 21262044 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention designed to increase the rate of secure infant attachment
Number of subjects: 0
Study 21262044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21262044 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 0
Study 18567877 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/kg of IVIG over 2 days
Number of subjects: 51
Study 18567877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 51
Study 16484440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (KETO)
Number of subjects: 13
Study 16484440 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-nitro-L-arginine methyl ester (L-NAME)
Number of subjects: 13
Study 16484440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of KETO and L-NAME
Number of subjects: 13
Study 16484440 — intervention group
Group type: COMPARATOR
Intervention: Control site (Ringer solution)
Number of subjects: 13
Study 16484440 — intervention group
Group type: COMPARATOR
Intervention: Local heating with KETO
Number of subjects: 13
Study 16484440 — intervention group
Group type: COMPARATOR
Intervention: Local heating with L-NAME
Number of subjects: 13
Study 12547382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain anxiety
Number of subjects: 70
Study 12547382 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 70
Study 12547382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of negative evaluation
Number of subjects: 70
Study 10846252 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate regimen with constant dose
Number of subjects: 67
Study 10846252 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate regimen with initial loading dose
Number of subjects: 67
Study 10846252 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic regimen of two capsules daily for three months
Number of subjects: 67
Study 9109283 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative goal setting
Number of subjects: 0
Study 9109283 — intervention group
Group type: COMPARATOR
Intervention: Assigned goal setting
Number of subjects: 0
Study 8257138 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg AZT with breakfast (B)
Number of subjects: 27
Study 8257138 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg AZT with breakfast (B)
Number of subjects: 27
Study 8257138 — intervention group
Group type: COMPARATOR
Intervention: 100 mg AZT fasting (F)
Number of subjects: 27
Study 8257138 — intervention group
Group type: COMPARATOR
Intervention: 250 mg AZT fasting (F)
Number of subjects: 27
Study 8257138 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg AZT breakfast (B)
Number of subjects: 27
Study 8257138 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg AZT breakfast (B)
Number of subjects: 27
Study 2931047 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin as two 250‐mg tablets
Number of subjects: 18
Study 2931047 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin as one 500‐mg tablet
Number of subjects: 18
Study 2931047 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin solution
Number of subjects: 18
Study 30849341 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft dislocation (GD)
Number of subjects: 1090
Study 30849341 — intervention group
Group type: COMPARATOR
Intervention: No graft dislocation (GD)
Number of subjects: 1090
Study 30849341 — intervention group
Group type: EXPERIMENTAL
Intervention: Early acutely elevated postoperative IOP
Number of subjects: 1090
Study 30849341 — intervention group
Group type: COMPARATOR
Intervention: No early acutely elevated postoperative IOP
Number of subjects: 1090
Study 30849341 — intervention group
Group type: EXPERIMENTAL
Intervention: History of elevated postoperative IOP beyond 1 month
Number of subjects: 1090
Study 30849341 — intervention group
Group type: COMPARATOR
Intervention: No history of elevated postoperative IOP beyond 1 month
Number of subjects: 1090
Study 29936600 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with epidural anesthesia (group GE)
Number of subjects: 90
Study 29936600 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (group G)
Number of subjects: 90
Study 27146169 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 2
Study 27146169 — intervention group
Group type: COMPARATOR
Intervention: Insufficient s‐25[OH]D <50 nmol/L
Number of subjects: 2
Study 27146169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient s‐25[OH]D >80 nmol/L
Number of subjects: 2
Study 22672713 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal conical connection with back-tapered collar and platform shifting design
Number of subjects: 34
Study 22672713 — intervention group
Group type: COMPARATOR
Intervention: External-hexagon implants with flat-to-flat implant-abutment interface
Number of subjects: 34
Study 22672713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant designs
Number of subjects: 34
Study 22520306 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light-filtering IOL (Oculaid PC 440Y Orange Series)
Number of subjects: 22
Study 22520306 — intervention group
Group type: COMPARATOR
Intervention: UV light-filtering IOL (Oculaid PC 430 Elite Series)
Number of subjects: 22
Study 21085758 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic left thoracic sympathetic blockade
Number of subjects: 15
Study 21085758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 18543158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treatment protocol (passive extension with a rubber band system)
Number of subjects: 21
Study 18543158 — intervention group
Group type: COMPARATOR
Intervention: Active treatment protocol (early active extension of the thumb)
Number of subjects: 21
Study 15967908 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Number of subjects: 12
Study 15967908 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Number of subjects: 12
Study 12623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg IV on day 1) + IL-2 (0.25 to 3 x 10^6 IU/m2 continuous IV infusion from day 3 to day 8)
Number of subjects: 19
Study 12623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate + modified IL-2 (6-hour bolus IV infusions from day 1-6)
Number of subjects: 19
Study 12623838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate + low-dose IL-2
Number of subjects: 19
Study 10580431 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII plus troglitazone (600 mg/day)
Number of subjects: 20
Study 10580431 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII plus metformin (1,700 mg/day)
Number of subjects: 20
Study 10580431 — intervention group
Group type: COMPARATOR
Intervention: CSII alone
Number of subjects: 20
Study 10163296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study 10163296 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 0
Study 1864117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 12
Study 1864117 — intervention group
Group type: COMPARATOR
Intervention: Protriptyline
Number of subjects: 12
Study 6888837 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 2% with epinephrine 1:200,000
Number of subjects: 62
Study 6888837 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1% plain
Number of subjects: 62
Study 6888837 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1% with epinephrine 1:200,000
Number of subjects: 62
Study 31142947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Itraconazole for 4 weeks
Number of subjects: 320
Study 31142947 — intervention group
Group type: COMPARATOR
Intervention: Oral Terbinafine for 4 weeks
Number of subjects: 320
Study 28535154 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary tube feeding immediately following tube placement
Number of subjects: 131
Study 28535154 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 131